Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, a Chinese biopharmaceutical company, have formed a strategic partnership. The agreement centers on the development and commercialization of Actair®, Stallergenes Greer‘s sublingual immunotherapy (SLIT) tablet for house dust mite (HDM) allergy treatment within China.
Under the terms of the agreement, the companies will collaborate on the regulatory approval process for Actair® in China. Nuance Pharma will then handle the subsequent commercialization of the product within the Chinese market.
Stallergenes Greer’s CEO, Dr. Andreas Amrein, expressed enthusiasm for the partnership. He highlighted the combined strengths of both companies—Stallergenes Greer’s experience in respiratory allergen immunotherapy and Nuance Pharma’s market access expertise and established commercial infrastructure in China—as key factors in accelerating patient access to Actair®. He emphasized the company’s commitment to providing treatment options for those suffering from HDM allergies and expanding access globally.
Nuance Pharma’s CEO and founder, Mark Lotter, stated that respiratory disease is a key focus for his company, and Actair® aligns perfectly with their portfolio and strategic goals. He expects a successful collaboration with Stallergenes Greer to bring innovative therapies to Chinese patients.
The prevalence of HDM-induced allergic rhinitis in China is substantial, affecting nearly 18% of the population. The number of patients receiving allergen immunotherapy treatment has seen significant growth in recent years, reflecting a growing need for effective treatment options. The potential market size for AIT in China is considerable, with predictions suggesting it could become the world’s largest market within a decade.
Current Chinese guidelines recommend AIT as a first-line treatment, especially for moderate to severe cases of allergic rhinitis. However, limited infrastructure and awareness have hindered wider adoption. Actair®, with its convenient tablet form, offers a promising solution to improve access for those living with HDM-induced allergies.
Actair® is already available in 21 countries and territories under various brand names. This partnership represents a significant step for Stallergenes Greer in expanding access to its immunotherapy treatments in high-need markets.
Allergic rhinitis is a widespread condition affecting hundreds of millions globally. Symptoms can range from sneezing and nasal congestion to itchy eyes and can significantly impact quality of life.
Nuance Pharma is a Chinese biopharmaceutical company specializing in specialty care, with a focus on respiratory diseases, pain management, and other therapeutic areas. The company employs a dual-wheel model, which combines the development of innovative therapies with self-sustaining commercial operations in China and the broader Asia-Pacific region.
Stallergenes Greer, based in Baar, Switzerland, is a global healthcare company focused on allergy diagnosis and treatment, providing allergen immunotherapy products and services in over 40 countries.
Related
